News|Videos|August 3, 2021
Predictive and Prognostic Factors In Chemotherapy-Ineligible AML
Author(s)Eytan Stein, MD
Eytan Stein, MD, discusses the predictive and prognostic factors for patients with chemotherapy-ineligible acute myeloid leukemia.
Advertisement
Episodes in this series
Advertisement
Related to this article
Experts discuss why the convenience of the all-oral decitabine/cedazuridine plus venetoclax regimen does not reduce the need for close monitoring in AML.
The approval expands the indication of pirtobrutinib to patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma with no known 17p deletion.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Atezolizumab/Chemo for Stage III dMMR Colon Cancer
2
Building out a Radiopharmaceuticals Program in Oncology Care
3
Iberdomide Combination Doubles PFS vs SOC Therapy in R/R Multiple Myeloma
4
How Would a TALAPRO-3 Approval Affect HRR-Altered Metastatic HSPC Care?
5